PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder program… Read more
Market Cap & Net Worth: PhaseRx Inc (PZRXQ)
PhaseRx Inc (PINK:PZRXQ) has a market capitalization of $2.34K ($2.34K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #48123 globally and #14809 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PhaseRx Inc's stock price $0.00 by its total outstanding shares 11690329 (11.69 Million).
PhaseRx Inc Market Cap History: 2016 to 2025
PhaseRx Inc's market capitalization history from 2016 to 2025. Data shows change from $18.12 Million to $2.34K (-68.02% CAGR).
PhaseRx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PhaseRx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PZRXQ by Market Capitalization
Companies near PhaseRx Inc in the global market cap rankings as of March 18, 2026.
Key companies related to PhaseRx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PhaseRx Inc Historical Marketcap From 2016 to 2025
Between 2016 and today, PhaseRx Inc's market cap moved from $18.12 Million to $ 2.34K, with a yearly change of -68.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.34K | 0.00% |
| 2024 | $2.34K | 0.00% |
| 2023 | $2.34K | +100.00% |
| 2022 | $1.17K | -50.00% |
| 2021 | $2.34K | -92.59% |
| 2020 | $31.56K | +285.71% |
| 2019 | $8.18K | -75.00% |
| 2018 | $32.73K | -99.28% |
| 2017 | $4.56 Million | -74.84% |
| 2016 | $18.12 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PhaseRx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.34K USD |
| MoneyControl | $2.34K USD |
| MarketWatch | $2.34K USD |
| marketcap.company | $2.34K USD |
| Reuters | $2.34K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.